Novo Nordisk’s Saxenda Receives European Regulatory Approval
Novo Nordisk has confirmed that their obesity drug, Saxenda, has received regulatory approval from the European Commission. The announcement follows earlier regulatory approval by the EMA (European Medicines Agency) in January and by the US FDA (Food and Drug Administration) in December. Specifically, the approval allows Saxenda to be used in patients who have an